MedTrace Logo

I-DROP MGD Symptomatic Relief and Tear Film Stability

NCT05011708 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-03-29

No results posted yet for this study

Summary

The objective of the study is to compare the difference in tear film stability and symptomatic relief between I-DROP MGD and another commercially available drop in the Canadian market.

Conditions

  • Dry Eye

Interventions

DEVICE

I-DROP MGD

I-DROP MGD are eye drop produced by I-MED PHARMA for the management of moderate to severe Dry Eye Disease.

DEVICE

Thealoz Duo

I-DROP MGD are eye drop produced by Laboratoires Thea for the management of Dry Eye Disease.

Sponsors & Collaborators

  • University of Waterloo

    collaborator OTHER

  • I-MED Pharma

    lead INDUSTRY

Principal Investigators

  • Lyndon Jones, Ph.D. · Centre for Ocular Research and Education

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2021-12-15
Completion
2022-01-12

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05011708 on ClinicalTrials.gov